Literature DB >> 29342471

Extra-articular manifestations and burden of disease in patients with radiographic and non-radiographic axial spondyloarthritis.

Kemal Erol1, Kevser Gok1, Gizem Cengiz1, Gamze Kilic2, Erkan Kilic3, Salih Ozgocmen4.   

Abstract

OBJECTIVE: Although the prevalence of peripheral and extra-articular disease in ankylosing spondylitis (AS) has been assessed in many studies, data on non-radiographic axial spondyloarthritis (nr-axSpA) is scanty. The aim of this study was first, to compare radiographic-axSpA/AS (r-axSpA/AS) and nr-axSpA concerning peripheral arthritis and extra-articular manifestations (EAMs), and second, to assess potential differences between patient subgroups with or without EAMs regarding disease burden.
METHODS: Data was extracted from our single center axSpA database. Patients having at least one of the EAMs (uveitis and/or inflammatory bowel disease (IBD) and/or psoriasis) were compared to those who did not have EAMs. Patients' clinical data including disease activity, functional and psychological status, physical limitations, quality of life (QoL) and magnetic resonance imaging of sacroiliac joints (SIJ MR) were evaluated.
RESULTS: Patients with nr-axSpA (n=193) were younger, had female predominance, better functional and physical status, higher frequency of bone edema in SIJ MR and peripheral arthritis but similar QoL, prevalence of HLA B27 and EAMs compared to r-axSpA/AS (n=352). The prevalence of current or ever uveitis (14.5 vs 15.3%, p=0.791), psoriasis (6.2 vs 5.4%, p=0.689) or IBD (4.1 vs 3.4%, p=0.663) in nr-axSpA and r-axSpA/AS were similar. In both subgroup of patients, EAMs positive and negative patients had similar functional status and QoL, as well as disease activity and laboratory parameters.
CONCLUSION: Patients with nr-axSpA and r-axSpA/AS have similar prevalence of EAMs and clinical burden of disease. Having EAMs does not have a major influence on clinical parameters and patient reported outcome measures in nr-axSpA and r-axSpA/AS.

Entities:  

Mesh:

Year:  2018        PMID: 29342471

Source DB:  PubMed          Journal:  Acta Reumatol Port        ISSN: 0303-464X            Impact factor:   1.290


  7 in total

Review 1.  Expert recommendations on early diagnosis and referral of axial spondyloarthritis in the Kingdom of Saudi Arabia.

Authors:  Hanan Al Rayes; Mansour Alazmi; Khaled Alderaan; Mushabab Alghamdi; Nayef Alghanim; Ahmed Alhazmi; Nadeer Alkhadhrawi; Mohammad Almohideb; Zeyad Alzahrani; Mohamed Bedaiwi; Hussein Halabi; Suzan Attar
Journal:  Clin Rheumatol       Date:  2022-01-08       Impact factor: 2.980

2.  Non-radiographic axial spondyloarthritis in Tunisia: main characteristics and detailed comparison with ankylosing spondylitis.

Authors:  Kawther Ben Abdelghani; Yosra Gzam; Alia Fazaa; Saoussen Miladi; Meriem Sellami; Leila Souabni; Selma Kassab; Selma Chekili; Leith Zakraoui; Ahmed Laater
Journal:  Clin Rheumatol       Date:  2020-09-24       Impact factor: 2.980

3.  Not All Rashes Are Allergic: Keratoderma Blennorrhagicum-Like Rash Masquerading as Contact Dermatitis.

Authors:  Maxwell Y Li; Jason Kolfenbach; Alan Schocket
Journal:  Allergy Rhinol (Providence)       Date:  2018-12-04

4.  Does Gender Impact a Diagnosis of Ankylosing Spondylitis?

Authors:  Mark C Hwang; Martin Rozycki; David Kauffman; Theresa Arndt; Esther Yi; Michael H Weisman
Journal:  ACR Open Rheumatol       Date:  2022-03-29

5.  Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries.

Authors:  Philip J Mease; Mei Liu; Sabrina Rebello; Hyungjoo Kang; Esther Yi; Yujin Park; Jeffrey D Greenberg
Journal:  Rheumatol Ther       Date:  2019-09-16

6.  Axial spondyloarthritis 10 years on: still looking for the lost tribe.

Authors:  Rosemarie Barnett; Thomas Ingram; Raj Sengupta
Journal:  Rheumatology (Oxford)       Date:  2020-10-01       Impact factor: 7.580

7.  Investigating diagnosis, treatment, and burden of disease in patients with ankylosing spondylitis in Central Eastern Europe and the United States: a real-world study.

Authors:  T Korotaeva; O Dina; E Holdsworth; L Fallon; G Milligan; S Meakin; L Wang; R Vasilescu; J C Cappelleri; A Deodhar
Journal:  Clin Rheumatol       Date:  2021-07-28       Impact factor: 2.980

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.